中国生物制药M701双特异性抗体新药申请获国家药监局受理

美股速递05-07

中国生物制药宣布，其研发的靶向CD3/EpCAM双特异性抗体M701的新药临床试验申请已正式获得中国国家药品监督管理局药品审评中心受理。

M701作为创新双特异性抗体药物，能够同时靶向CD3与EpCAM两个靶点，通过激活T细胞特异性杀伤EpCAM阳性肿瘤细胞，为晚期实体瘤患者提供新的治疗选择。此次新药申请获受理标志着该药物研发取得重要进展，后续将按程序开展临床审评工作。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1177407251?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-07 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177407251","market":"us","top_or_hot":-1,"title":"中国生物制药M701双特异性抗体新药申请获国家药监局受理","media":"美股速递","content":"<p>中国生物制药宣布，其研发的靶向CD3/EpCAM双特异性抗体M701的新药临床试验申请已正式获得中国国家药品监督管理局药品审评中心受理。</p>\n<p>M701作为创新双特异性抗体药物，能够同时靶向CD3与EpCAM两个靶点，通过激活T细胞特异性杀伤EpCAM阳性肿瘤细胞，为晚期实体瘤患者提供新的治疗选择。此次新药申请获受理标志着该药物研发取得重要进展，后续将按程序开展临床审评工作。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中国生物制药M701双特异性抗体新药申请获国家药监局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中国生物制药M701双特异性抗体新药申请获国家药监局受理\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-07 16:38 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>中国生物制药宣布，其研发的靶向CD3/EpCAM双特异性抗体M701的新药临床试验申请已正式获得中国国家药品监督管理局药品审评中心受理。\nM701作为创新双特异性抗体药物，能够同时靶向CD3与EpCAM两个靶点，通过激活T细胞特异性杀伤EpCAM阳性肿瘤细胞，为晚期实体瘤患者提供新的治疗选择。此次新药申请获受理标志着该药物研发取得重要进展，后续将按程序开展临床审评工作。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1177407251","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177407251","pubTimestamp":1778143138,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"中国生物制药宣布，其研发的靶向CD3/EpCAM双特异性抗体M701的新药临床试验申请已正式获得中国国家药品监督管理局药品审评中心受理。\nM701作为创新双特异性抗体药物，能够同时靶向CD3与EpCAM两个靶点，通过激活T细胞特异性杀伤EpCAM阳性肿瘤细胞，为晚期实体瘤患者提供新的治疗选择。此次新药申请获受理标志着该药物研发取得重要进展，后续将按程序开展临床审评工作。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","01177":"中国生物制药","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1589":"北水核心资产"},"translate_title":"China Biopharmaceutical's M701 bispecific antibody new drug application was accepted by the State Food and Drug Administration","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"中国生物制药宣布，其研发的靶向CD3/EpCAM双特异性抗体M701的新药临床试验申请已正式获得中国国家药品监督管理局药品审评中心受理。\nM701作为创新双特异性抗体药物，能够同时靶向CD3与EpCAM两个靶点，通过激活T细胞特异性杀伤EpCAM阳性肿瘤细胞，为晚期实体瘤患者提供新的治疗选择。此次新药申请获受理标志着该药物研发取得重要进展，后续将按程序开展临床审评工作。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177407251","isCrawlerRequest":true}